Drugs / LY3031207
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01632566 | Jun 2012 → Apr 2013 | — | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01449630 | Oct 2011 → Apr 2012 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3031207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01449630 ↗ |
| Modality | Small molecule | — CHEMBL2152712 ↗ |
| Route | Oral | “Administered orally” NCT01449630 ↗ |